Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection.

Abstract

Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma-reactive T cells at the primary site of melanoma and has a high rate of histological complete response, the pre-surgical administration of this combination could be the optimal therapy for unresectable advanced melanoma. In this report, a case of unresectable advanced melanoma treated successfully with administration of nivolumab with ipilimumab before primary tumor resection is presented. In addition, CD8+ T cells increased among the tumor-infiltrating lymphocytes that were surrounding melanoma cells and caspase 3+ cells. The present case suggests that pre-surgical administration of nivolumab with ipilimumab could be the optimal therapy for the treatment of unresectable advanced melanoma.

• Authors: Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Ryo Amagai, Akira Hashimoto, Takanori Hidaka, Setsuya Aiba
• Journal: Frontiers in medicine (Front Med (Lausanne)) Vol. 6 Pg. 140 ( 2019) ISSN: 2296-858X [Print] Switzerland
• PMID: 31297373 (Publication Type: Case Reports)